We've updated our Privacy Policy to make it clearer how we use your personal data. We use cookies to provide you with a better experience. You can read our Cookie Policy here.

Advertisement
Sign up to read this article for FREE!

After signing up, you'll start to receive regular news updates from us.

Applied Biosystems and Eppendorf Announce Licensing Agreement

Listen with
Speechify
0:00
Register for free to listen to this article
Thank you. Listen to this article using the player above.

Want to listen to this article for FREE?

Complete the form below to unlock access to ALL audio articles.

Read time: Less than a minute

Applied Biosystems Group, an Applera Corporation business, has announced it has granted a worldwide, royalty-bearing license to Eppendorf AG under a real-time thermal cycler patent rights agreement.

Under the agreement, Eppendorf will have the right to manufacture and sell real-time thermal cyclers in the research and applied fields.

"This agreement with Eppendorf further validates the significance of Applied Biosystems' real-time thermal cycler technology," said Paul D. Grossman, Ph.D., Esq., Vice President, Strategic Planning, Business Development and Intellectual Property for Applied Biosystems.

"We may consider entering into additional licenses with high quality vendors under the right terms."

"We are pleased to announce our agreement with Applied Biosystems," said Klaus Fink, CEO and President of Eppendorf AG.

"We are committed to providing our customers with access to technologies that are of greatest importance for the life sciences sector."

"Our new product generation of real-time cyclers ensures best practices in laboratories in terms of productivity, simplicity, and ease of use."

The license to Eppendorf is based on U.S. Patent No. 6,814,934 and foreign equivalents.

The U.S. Patent & Trademark Office (USPTO) granted Applera this fundamental patent pertaining to real-time PCR instrumentation in November 2004.